Adjunctive fluoxetine improves global function in chronic schizophrenia.
Eight chronic schizophrenic inpatients received adjunctive fluoxetine (20 mg/day) for a mean of 10.6 weeks in an open clinical trial. Clinical state improved in all patients. Violent incidents decreased, while participation in programs and socialization increased.
Goldman
M B
MB
Elgin Mental Health Center, Illinois.
Janecek
H M
HM
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D003192:Compulsive Behavior / Q000188:drug therapy / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D004359:Drug Therapy, Combination; D005473:Fluoxetine / Q000008:administration & dosage*; D006801:Humans; D006842:Hydrocarbons, Brominated / Q000506:poisoning*; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D006842:Hydrocarbons, Brominated; D005473:Fluoxetine; C037530:1,1,2,2-tetrabromoethane